Clinical trial
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With…
NCT00472420 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00472420 |
|---|---|
| Title | A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. |
| Official title | An Open-label Study of the Effect of the Addition of MabThera to Standard Chemotherapy on Clinical Response in Patients With Previously Untreated Mantle Cell Lymphoma |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mantle Cell Lymphoma |
| Intervention type | Drug |
| Interventions | rituximab [MabThera/Rituxan], First line chemotherapy |
| Enrollment | 48 |
| Start date | Jun 27, 2007 |
| Primary completion | May 25, 2011 |
| Completion | May 25, 2011 |
| First posted | May 11, 2007 |
| Last update posted | Aug 15, 2017 |
| Countries | Hungary |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: